In:
Journal of the National Comprehensive Cancer Network, Harborside Press, LLC, Vol. 20, No. 6 ( 2022-06), p. 622-634
Kurzfassung:
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
Materialart:
Online-Ressource
ISSN:
1540-1405
,
1540-1413
DOI:
10.6004/jnccn.2022.0031
Sprache:
Unbekannt
Verlag:
Harborside Press, LLC
Publikationsdatum:
2022